Sanofi to di­vest can­cer biotech it bought for $1B, axe 100 staffers in Cal­i­for­nia

Sanofi is set to di­vest a site and as­sets un­der Amu­nix Phar­ma­ceu­ti­cals, an im­muno-on­col­o­gy biotech it ac­quired for $1 bil­lion around three years ago. The com­pa­ny will al­so be lay­ing off 100 work­ers at the site in San Fran­cis­co.

The com­pa­ny has “ac­tive­ly scout­ed for buy­ers to take over re­search, CMC and clin­i­cal ac­tiv­i­ties,” a Sanofi spokesper­son told End­points News. “We have made progress and are in ac­tive dis­cus­sions with po­ten­tial part­ners. We ex­pect to make fi­nal de­ter­mi­na­tions in the next few months.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER